The CooperCOO +4.04%85 WACC % is 7.66% as of Jun. 24, 2026, which is 3% above its 10-year median of 7.47. GuruFocus rates COO with a GF Score™ of 85/100 and a GF Value™ of $100.85 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 866 Medical Devices & Instruments companies, The Cooper ranks better than 60.97% on this metric.
As of today (2026-06-24), The Cooper's weighted average cost of capital is 7.66%%. The Cooper's ROIC % is 2.38% (calculated using TTM income statement data).
The Cooper earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
The Cooper (NAS:COO) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, The Cooper's weighted average cost of capital is 7.66%%. The Cooper's ROIC % is 2.38% (calculated using TTM income statement data).
The Cooper earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
Related Terms
The Cooper WACC % Historical Data
* Premium members only.
The historical data trend for The Cooper's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, The Cooper's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper WACC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's WACC % distribution charts can be found below:
* The bar in red indicates where The Cooper's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, The Cooper's market capitalization (E) is $13423.959 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Apr. 2026, The Cooper's latest one-year quarterly average Book Value of Debt (D) is $2505.78 Mil.
a) weight of equity = E / (E + D) = 13423.959 / (13423.959 + 2505.78) = 0.8427
b) weight of debt = D / (E + D) = 2505.78 / (13423.959 + 2505.78) = 0.1573
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.398%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. The Cooper's beta is 0.7166.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.398% + 0.7166 * 6% = 8.6976%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Apr. 2026, The Cooper's interest expense (positive number) was $93.1 Mil. Its total Book Value of Debt (D) is $2505.78 Mil.
Cost of Debt = 93.1 / 2505.78 = 3.7154%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 176.7 / 412.5 = 42.84%.
The Cooper's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC
=
E / (E + D)
*
Cost of Equity
+
D / (E + D)
*
Cost of Debt
*
(1 - Tax Rate)
=
0.8427
*
8.6976%
+
0.1573
*
3.7154%
*
(1 - 42.84%)
=
7.66%
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a WACC % of 7.66% as of Jun. 24, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on The Cooper and its competitors. This is near median its historical median of 7.47. Over the past decade, The Cooper's WACC % has ranged from 5.00 to 10.32. According to the industry distribution chart, The Cooper ranks #338 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 39%.
Is The Cooper's WACC % too high?
The Cooper's current WACC % of 7.66% is near median its 10-year median of 7.47. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 10.32. The Medical Devices & Instruments industry median WACC % is 9.24. The Cooper's value of 7.66% is 17.1% below this industry median. Based on the distribution chart, The Cooper ranks #338 out of 866 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, The Cooper has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's WACC % compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #338 out of 866 companies for WACC %. This puts The Cooper in the upper half of its industry. The industry median WACC % is 9.24. The Cooper's value of 7.66% is 17.1% below this benchmark. Historically, The Cooper's own WACC % has ranged from 5.00 to 10.32 over the past decade. While the company's 10-year median is 7.47 vs. the industry median of 9.24, The Cooper has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Medical Devices & Instruments company?
The median WACC % among Medical Devices & Instruments companies is 9.24, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current WACC % of 7.66% is 17.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median WACC % is 9.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current WACC % is 7.66%, which is near median its own 10-year median of 7.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $100.85, compared to a current price of $68.83 — trading 31.8% below its estimated fair value. The current WACC % is 7.66%, which is near median its 10-year median of 7.47 and 17.1% below the Medical Devices & Instruments industry median of 9.24. The Cooper's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For The Cooper (COO), the current WACC % is 7.66% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $68.83 is trading 31.8% below its estimated GF Value™ of $100.85.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
WACC %: 7.66% (near median its 10-year median of 7.47)
GF Value™: $100.85 vs. price of $68.83 (31.8% below fair value)
Industry Position: 17.1% below the Medical Devices & Instruments median (#338 of 866)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
85GF Score
Get the complete analysis for COO
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
